Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.

Brown, Timothy J; Mamtani, Ronac; Gimotty, Phyllis A; Karasic, Thomas B; Yang, Yu-Xiao

Brown, Timothy J; Mamtani, Ronac; Gimotty, Phyllis A; Karasic, Thomas B; Yang, Yu-Xiao.

Affiliation

Brown TJ; Abramson Cancer Center, University of Pennsylvania, 12 Perelman Ctr South Pavilion, 3400 Civic Center Blvd, Philadelphia, PA, 19104-4283, USA. Timothy.Brown3@pennmedicine.upenn.edu.
Mamtani R; Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA, USA. Timothy.Brown3@pennmedicine.upenn.edu.
Gimotty PA; Abramson Cancer Center, University of Pennsylvania, 12 Perelman Ctr South Pavilion, 3400 Civic Center Blvd, Philadelphia, PA, 19104-4283, USA.
Karasic TB; Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia, PA, USA.
Yang YX; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.

J Cancer Res Clin Oncol ; 149(6): 2345-2354, 2023 Jun.

Article in En | MEDLINE | ID: mdl-36862158

Subject(s)

Carcinoma, Hepatocellular; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Humans; Bevacizumab; Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/drug therapy; Ethanol

Key words

Hepatocellular carcinoma; Immunotherapy; NASH; Outcomes

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Non-alcoholic Fatty Liver Disease / Liver Neoplasms Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Cancer Res Clin Oncol Year: 2023 Document type: Article Affiliation country: United States Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google